Treatment of Refractory Cystoid Macular Edema with Pegylated Interferon Alfa-2A: A Retrospective Chart Review

Hillary C. Stiefel, Laura J. Kopplin, Thomas Albini, Michael Chang, Sravanthi Vegunta, Eric B. Suhler

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Purpose: To determine the efficacy of pegylated interferon alfa-2A in the treatment of refractory inflammatory cystoid macular edema (CME) Methods: Retrospective chart review Results: Treatment with pegylated interferon alfa-2A led to an improvement in CME in all eyes of seven included patients, with a mean decrease in CMT from 478 µm to 310 µm (p <.05). The vision in one patient did not improve due to preexisting retinal atrophy. All other eyes showed improvement in vision, with a mean improvement in best LogMAR visual acuity from +0.59 to +0.28 (p <.05). The treatment effect was sustained with low-dose treatment every 2 weeks or less in the majority of patients. Two patients who stopped interferon treatment given flu-like symptoms and intolerable rash, respectively, showed rapid recurrence of CME. Conclusions: Weekly administration of pegylated interferon alfa-2A is an effective treatment for refractory inflammatory CME, though side effects may limit tolerability in some patients.

Original languageEnglish (US)
JournalOcular Immunology and Inflammation
DOIs
StateAccepted/In press - Jan 1 2019

Keywords

  • cystoid macular edema
  • Pegylated interferon (peginterferon alfa-2A)
  • uveitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Ophthalmology

Fingerprint Dive into the research topics of 'Treatment of Refractory Cystoid Macular Edema with Pegylated Interferon Alfa-2A: A Retrospective Chart Review'. Together they form a unique fingerprint.

  • Cite this